Research ExplorerPublicationsGenetic modifiers of menopausal hormone replacement therapy ...

Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study

Standard

Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study. / Rudolph, Anja; Hein, Rebecca; Lindström, Sara; Beckmann, Lars; Behrens, Sabine; Liu, Jianjun; Aschard, Hugues; Bolla, Manjeet K; Wang, Jean; Truong, Thérèse; Cordina-Duverger, Emilie; Menegaux, Florence; Brüning, Thomas; Harth, Volker; Severi, Gianluca; Baglietto, Laura; Southey, Melissa; Chanock, Stephen J; Lissowska, Jolanta; Figueroa, Jonine D; Eriksson, Mikael; Humpreys, Keith; Darabi, Hatef; Olson, Janet E; Stevens, Kristen N; Vachon, Celine M; Knight, Julia A; Glendon, Gord; Mulligan, Anna Marie; Ashworth, Alan; Orr, Nicholas; Schoemaker, Minouk; Webb, Penny M; Guénel, Pascal; Brauch, Hiltrud; Giles, Graham; García-Closas, Montserrat; Czene, Kamila; Chenevix-Trench, Georgia; Couch, Fergus J; Andrulis, Irene L; Swerdlow, Anthony; Hunter, David J; Flesch-Janys, Dieter; Easton, Douglas F; Hall, Per; Nevanlinna, Heli; Kraft, Peter; Chang-Claude, Jenny; GENICA Network ; KConFab Investigators ; AOCS Management Grp ; Breast Canc Association Consortium .

In: ENDOCR-RELAT CANCER, Vol. 20, No. 6, 01.12.2013, p. 875-87.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rudolph, A, Hein, R, Lindström, S, Beckmann, L, Behrens, S, Liu, J, Aschard, H, Bolla, MK, Wang, J, Truong, T, Cordina-Duverger, E, Menegaux, F, Brüning, T, Harth, V, Severi, G, Baglietto, L, Southey, M, Chanock, SJ, Lissowska, J, Figueroa, JD, Eriksson, M, Humpreys, K, Darabi, H, Olson, JE, Stevens, KN, Vachon, CM, Knight, JA, Glendon, G, Mulligan, AM, Ashworth, A, Orr, N, Schoemaker, M, Webb, PM, Guénel, P, Brauch, H, Giles, G, García-Closas, M, Czene, K, Chenevix-Trench, G, Couch, FJ, Andrulis, IL, Swerdlow, A, Hunter, DJ, Flesch-Janys, D, Easton, DF, Hall, P, Nevanlinna, H, Kraft, P, Chang-Claude, J & GENICA Network ; KConFab Investigators ; AOCS Management Grp ; Breast Canc Association Consortium 2013, 'Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study', ENDOCR-RELAT CANCER, vol. 20, no. 6, pp. 875-87. https://doi.org/10.1530/ERC-13-0349

APA

Rudolph, A., Hein, R., Lindström, S., Beckmann, L., Behrens, S., Liu, J., Aschard, H., Bolla, M. K., Wang, J., Truong, T., Cordina-Duverger, E., Menegaux, F., Brüning, T., Harth, V., Severi, G., Baglietto, L., Southey, M., Chanock, S. J., Lissowska, J., ... GENICA Network ; KConFab Investigators ; AOCS Management Grp ; Breast Canc Association Consortium (2013). Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study. ENDOCR-RELAT CANCER, 20(6), 875-87. https://doi.org/10.1530/ERC-13-0349

Vancouver

Rudolph A, Hein R, Lindström S, Beckmann L, Behrens S, Liu J et al. Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study. ENDOCR-RELAT CANCER. 2013 Dec 1;20(6):875-87. https://doi.org/10.1530/ERC-13-0349

Bibtex

@article{e444530a17dd49e5b072e9c61854810d,
title = "Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study",
abstract = "Women using menopausal hormone therapy (MHT) are at increased risk of developing breast cancer (BC). To detect genetic modifiers of the association between current use of MHT and BC risk, we conducted a meta-analysis of four genome-wide case-only studies followed by replication in 11 case-control studies. We used a case-only design to assess interactions between single-nucleotide polymorphisms (SNPs) and current MHT use on risk of overall and lobular BC. The discovery stage included 2920 cases (541 lobular) from four genome-wide association studies. The top 1391 SNPs showing P values for interaction (Pint) <3.0 × 10(-3) were selected for replication using pooled case-control data from 11 studies of the Breast Cancer Association Consortium, including 7689 cases (676 lobular) and 9266 controls. Fixed-effects meta-analysis was used to derive combined Pint. No SNP reached genome-wide significance in either the discovery or combined stage. We observed effect modification of current MHT use on overall BC risk by two SNPs on chr13 near POMP (combined Pint≤8.9 × 10(-6)), two SNPs in SLC25A21 (combined Pint≤4.8 × 10(-5)), and three SNPs in PLCG2 (combined Pint≤4.5 × 10(-5)). The association between lobular BC risk was potentially modified by one SNP in TMEFF2 (combined Pint≤2.7 × 10(-5)), one SNP in CD80 (combined Pint≤8.2 × 10(-6)), three SNPs on chr17 near TMEM132E (combined Pint≤2.2×10(-6)), and two SNPs on chr18 near SLC25A52 (combined Pint≤4.6 × 10(-5)). In conclusion, polymorphisms in genes related to solute transportation in mitochondria, transmembrane signaling, and immune cell activation are potentially modifying BC risk associated with current use of MHT. These findings warrant replication in independent studies.",
author = "Anja Rudolph and Rebecca Hein and Sara Lindstr{\"o}m and Lars Beckmann and Sabine Behrens and Jianjun Liu and Hugues Aschard and Bolla, {Manjeet K} and Jean Wang and Th{\'e}r{\`e}se Truong and Emilie Cordina-Duverger and Florence Menegaux and Thomas Br{\"u}ning and Volker Harth and Gianluca Severi and Laura Baglietto and Melissa Southey and Chanock, {Stephen J} and Jolanta Lissowska and Figueroa, {Jonine D} and Mikael Eriksson and Keith Humpreys and Hatef Darabi and Olson, {Janet E} and Stevens, {Kristen N} and Vachon, {Celine M} and Knight, {Julia A} and Gord Glendon and Mulligan, {Anna Marie} and Alan Ashworth and Nicholas Orr and Minouk Schoemaker and Webb, {Penny M} and Pascal Gu{\'e}nel and Hiltrud Brauch and Graham Giles and Montserrat Garc{\'i}a-Closas and Kamila Czene and Georgia Chenevix-Trench and Couch, {Fergus J} and Andrulis, {Irene L} and Anthony Swerdlow and Hunter, {David J} and Dieter Flesch-Janys and Easton, {Douglas F} and Per Hall and Heli Nevanlinna and Peter Kraft and Jenny Chang-Claude and {GENICA Network ; KConFab Investigators ; AOCS Management Grp ; Breast Canc Association Consortium}",
year = "2013",
month = dec,
day = "1",
doi = "10.1530/ERC-13-0349",
language = "English",
volume = "20",
pages = "875--87",
journal = "ENDOCR-RELAT CANCER",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "6",

}

RIS

TY - JOUR

T1 - Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study

AU - Rudolph, Anja

AU - Hein, Rebecca

AU - Lindström, Sara

AU - Beckmann, Lars

AU - Behrens, Sabine

AU - Liu, Jianjun

AU - Aschard, Hugues

AU - Bolla, Manjeet K

AU - Wang, Jean

AU - Truong, Thérèse

AU - Cordina-Duverger, Emilie

AU - Menegaux, Florence

AU - Brüning, Thomas

AU - Harth, Volker

AU - Severi, Gianluca

AU - Baglietto, Laura

AU - Southey, Melissa

AU - Chanock, Stephen J

AU - Lissowska, Jolanta

AU - Figueroa, Jonine D

AU - Eriksson, Mikael

AU - Humpreys, Keith

AU - Darabi, Hatef

AU - Olson, Janet E

AU - Stevens, Kristen N

AU - Vachon, Celine M

AU - Knight, Julia A

AU - Glendon, Gord

AU - Mulligan, Anna Marie

AU - Ashworth, Alan

AU - Orr, Nicholas

AU - Schoemaker, Minouk

AU - Webb, Penny M

AU - Guénel, Pascal

AU - Brauch, Hiltrud

AU - Giles, Graham

AU - García-Closas, Montserrat

AU - Czene, Kamila

AU - Chenevix-Trench, Georgia

AU - Couch, Fergus J

AU - Andrulis, Irene L

AU - Swerdlow, Anthony

AU - Hunter, David J

AU - Flesch-Janys, Dieter

AU - Easton, Douglas F

AU - Hall, Per

AU - Nevanlinna, Heli

AU - Kraft, Peter

AU - Chang-Claude, Jenny

AU - GENICA Network ; KConFab Investigators ; AOCS Management Grp ; Breast Canc Association Consortium

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Women using menopausal hormone therapy (MHT) are at increased risk of developing breast cancer (BC). To detect genetic modifiers of the association between current use of MHT and BC risk, we conducted a meta-analysis of four genome-wide case-only studies followed by replication in 11 case-control studies. We used a case-only design to assess interactions between single-nucleotide polymorphisms (SNPs) and current MHT use on risk of overall and lobular BC. The discovery stage included 2920 cases (541 lobular) from four genome-wide association studies. The top 1391 SNPs showing P values for interaction (Pint) <3.0 × 10(-3) were selected for replication using pooled case-control data from 11 studies of the Breast Cancer Association Consortium, including 7689 cases (676 lobular) and 9266 controls. Fixed-effects meta-analysis was used to derive combined Pint. No SNP reached genome-wide significance in either the discovery or combined stage. We observed effect modification of current MHT use on overall BC risk by two SNPs on chr13 near POMP (combined Pint≤8.9 × 10(-6)), two SNPs in SLC25A21 (combined Pint≤4.8 × 10(-5)), and three SNPs in PLCG2 (combined Pint≤4.5 × 10(-5)). The association between lobular BC risk was potentially modified by one SNP in TMEFF2 (combined Pint≤2.7 × 10(-5)), one SNP in CD80 (combined Pint≤8.2 × 10(-6)), three SNPs on chr17 near TMEM132E (combined Pint≤2.2×10(-6)), and two SNPs on chr18 near SLC25A52 (combined Pint≤4.6 × 10(-5)). In conclusion, polymorphisms in genes related to solute transportation in mitochondria, transmembrane signaling, and immune cell activation are potentially modifying BC risk associated with current use of MHT. These findings warrant replication in independent studies.

AB - Women using menopausal hormone therapy (MHT) are at increased risk of developing breast cancer (BC). To detect genetic modifiers of the association between current use of MHT and BC risk, we conducted a meta-analysis of four genome-wide case-only studies followed by replication in 11 case-control studies. We used a case-only design to assess interactions between single-nucleotide polymorphisms (SNPs) and current MHT use on risk of overall and lobular BC. The discovery stage included 2920 cases (541 lobular) from four genome-wide association studies. The top 1391 SNPs showing P values for interaction (Pint) <3.0 × 10(-3) were selected for replication using pooled case-control data from 11 studies of the Breast Cancer Association Consortium, including 7689 cases (676 lobular) and 9266 controls. Fixed-effects meta-analysis was used to derive combined Pint. No SNP reached genome-wide significance in either the discovery or combined stage. We observed effect modification of current MHT use on overall BC risk by two SNPs on chr13 near POMP (combined Pint≤8.9 × 10(-6)), two SNPs in SLC25A21 (combined Pint≤4.8 × 10(-5)), and three SNPs in PLCG2 (combined Pint≤4.5 × 10(-5)). The association between lobular BC risk was potentially modified by one SNP in TMEFF2 (combined Pint≤2.7 × 10(-5)), one SNP in CD80 (combined Pint≤8.2 × 10(-6)), three SNPs on chr17 near TMEM132E (combined Pint≤2.2×10(-6)), and two SNPs on chr18 near SLC25A52 (combined Pint≤4.6 × 10(-5)). In conclusion, polymorphisms in genes related to solute transportation in mitochondria, transmembrane signaling, and immune cell activation are potentially modifying BC risk associated with current use of MHT. These findings warrant replication in independent studies.

U2 - 10.1530/ERC-13-0349

DO - 10.1530/ERC-13-0349

M3 - SCORING: Journal article

C2 - 24080446

VL - 20

SP - 875

EP - 887

JO - ENDOCR-RELAT CANCER

JF - ENDOCR-RELAT CANCER

SN - 1351-0088

IS - 6

ER -